These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17063397)

  • 41. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.
    Burke TG; Mi Z
    J Med Chem; 1994 Jan; 37(1):40-6. PubMed ID: 8289200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan.
    Casadó A; Sagristá ML; Mora M
    J Pharm Sci; 2014 Oct; 103(10):3127-38. PubMed ID: 25091422
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition.
    Dodds HM; Craik DJ; Rivory LP
    J Pharm Sci; 1997 Dec; 86(12):1410-6. PubMed ID: 9423156
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
    Iwase Y; Maitani Y
    Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
    J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs.
    Liu X; Lynn BC; Zhang J; Song L; Bom D; Du W; Curran DP; Burke TG
    J Am Chem Soc; 2002 Jul; 124(26):7650-1. PubMed ID: 12083906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines.
    Casadó A; Sagristá ML; Mora M
    Int J Nanomedicine; 2018; 13():5301-5320. PubMed ID: 30254436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
    Zastre J; Anantha M; Ramsay E; Bally M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):91-102. PubMed ID: 17009029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration.
    Din FU; Choi JY; Kim DW; Mustapha O; Kim DS; Thapa RK; Ku SK; Youn YS; Oh KT; Yong CS; Kim JO; Choi HG
    Drug Deliv; 2017 Nov; 24(1):502-510. PubMed ID: 28181835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
    Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
    Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol.
    Dos Santos N; Cox KA; McKenzie CA; van Baarda F; Gallagher RC; Karlsson G; Edwards K; Mayer LD; Allen C; Bally MB
    Biochim Biophys Acta; 2004 Feb; 1661(1):47-60. PubMed ID: 14967474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
    Semple SC; Leone R; Wang J; Leng EC; Klimuk SK; Eisenhardt ML; Yuan ZN; Edwards K; Maurer N; Hope MJ; Cullis PR; Ahkong QF
    J Pharm Sci; 2005 May; 94(5):1024-38. PubMed ID: 15793796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.
    Schoemaker NE; Rosing H; Jansen S; Schellens JH; Beijnen JH
    Ther Drug Monit; 2003 Feb; 25(1):120-4. PubMed ID: 12548157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization.
    Zhao H; Lee C; Sai P; Choe YH; Boro M; Pendri A; Guan S; Greenwald RB
    J Org Chem; 2000 Jul; 65(15):4601-6. PubMed ID: 10959865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
    Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
    Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine.
    Burke TG; Gao X
    J Pharm Sci; 1994 Jul; 83(7):967-9. PubMed ID: 7965676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.
    Lau UY; Benoit LT; Stevens NS; Emmerton KK; Zaval M; Cochran JH; Senter PD
    Mol Pharm; 2018 Sep; 15(9):4063-4072. PubMed ID: 30067902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
    Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
    Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention.
    Zhigaltsev IV; Maurer N; Edwards K; Karlsson G; Cullis PR
    J Control Release; 2006 Jan; 110(2):378-386. PubMed ID: 16318894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.